|
1
|
Jiang D, Zhang J, Shen W, Sun Y, Wang Z, Wang J, Zhang J, Zhang G, Zhang G, Wang Y, Cai S, Zhang J, Wang Y, Liu R, Bai T, Sun Y, Yang S, Ma Z, Li Z, Li J, Ma C, Cheng L, Sun B, Yang K. DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection. Vaccines (Basel) 2024; 12:928. [PMID: 39204051 PMCID: PMC11359959 DOI: 10.3390/vaccines12080928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2024] [Revised: 08/06/2024] [Accepted: 08/14/2024] [Indexed: 09/03/2024] Open
Abstract
Vaccines has long been the focus of antiviral immunotherapy research. Viral epitopes are thought to be useful biomarkers for immunotherapy (both antibody-based and cellular). In this study, we designed a novel vaccine molecule, the Hantaan virus (HTNV) glycoprotein (GP) tandem Th epitope molecule (named the Gnc molecule), in silico. Subsequently, computer analysis was used to conduct a comprehensive and in-depth study of the various properties of the molecule and its effects as a vaccine molecule in the body. The Gnc molecule was designed for DNA vaccines and optimized with a lysosomal-targeting membrane protein (LAMP) strategy. The effects of GP-derived Th epitopes and multiepitope vaccines were initially verified in animals. Our research has resulted in the design of two vaccines based on effective antiviral immune targets. The effectiveness of molecular therapies has also been preliminarily demonstrated in silico and in laboratory animals, which lays a foundation for the application of a vaccines strategy in the field of antivirals.
Collapse
Affiliation(s)
- Dongbo Jiang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
- Department of Microbiology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China;
| | - Junqi Zhang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Wenyang Shen
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Yubo Sun
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Zhenjie Wang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Jiawei Wang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Jinpeng Zhang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Guanwen Zhang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Gefei Zhang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Yueyue Wang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Sirui Cai
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Jiaxing Zhang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Yongkai Wang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Ruibo Liu
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Tianyuan Bai
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Yuanjie Sun
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Shuya Yang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Zilu Ma
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Zhikui Li
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Jijin Li
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Chenjin Ma
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| | - Linfeng Cheng
- Department of Microbiology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China;
| | - Baozeng Sun
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
- Yingtan Detachment, Jiangxi General Hospital, Chinese People’s Armed Police Force, Nanchang 330001, China
| | - Kun Yang
- Department of Immunology, The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi’an 710032, China; (D.J.); (J.Z.); (W.S.); (Y.S.); (Z.W.); (J.W.); (J.Z.); (G.Z.); (G.Z.); (Y.W.); (S.C.); (J.Z.); (Y.W.); (R.L.); (T.B.); (Y.S.); (S.Y.); (Z.M.); (Z.L.); (J.L.); (C.M.)
| |
Collapse
|
|
2
|
Tobias J, Steinberger P, Wilkinson J, Klais G, Kundi M, Wiedermann U. SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity. Vaccines (Basel) 2024; 12:795. [PMID: 39066432 PMCID: PMC11281395 DOI: 10.3390/vaccines12070795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Revised: 07/10/2024] [Accepted: 07/15/2024] [Indexed: 07/28/2024] Open
Abstract
Immunity against respiratory pathogens is often short-term, and, consequently, there is an unmet need for the effective prevention of such infections. One such infectious disease is coronavirus disease 19 (COVID-19), which is caused by the novel Beta coronavirus SARS-CoV-2 that emerged around the end of 2019. The World Health Organization declared the illness a pandemic on 11 March 2020, and since then it has killed or sickened millions of people globally. The development of COVID-19 systemic vaccines, which impressively led to a significant reduction in disease severity, hospitalization, and mortality, contained the pandemic's expansion. However, these vaccines have not been able to stop the virus from spreading because of the restricted development of mucosal immunity. As a result, breakthrough infections have frequently occurred, and new strains of the virus have been emerging. Furthermore, SARS-CoV-2 will likely continue to circulate and, like the influenza virus, co-exist with humans. The upper respiratory tract and nasal cavity are the primary sites of SARS-CoV-2 infection and, thus, a mucosal/nasal vaccination to induce a mucosal response and stop the virus' transmission is warranted. In this review, we present the status of the systemic vaccines, both the approved mucosal vaccines and those under evaluation in clinical trials. Furthermore, we present our approach of a B-cell peptide-based vaccination applied by a prime-boost schedule to elicit both systemic and mucosal immunity.
Collapse
Affiliation(s)
- Joshua Tobias
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria
| | - Peter Steinberger
- Division of Immune Receptors and T Cell Activation, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria;
| | - Joy Wilkinson
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria
| | - Gloria Klais
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria
| | - Michael Kundi
- Department of Environmental Health, Center for Public Health, Medical University of Vienna, 1090 Vienna, Austria;
| | - Ursula Wiedermann
- Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria
| |
Collapse
|
|
3
|
Zhao Z, Bashiri S, Ziora ZM, Toth I, Skwarczynski M. COVID-19 Variants and Vaccine Development. Viruses 2024; 16:757. [PMID: 38793638 PMCID: PMC11125726 DOI: 10.3390/v16050757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Revised: 05/08/2024] [Accepted: 05/08/2024] [Indexed: 05/26/2024] Open
Abstract
Coronavirus disease 2019 (COVID-19), the global pandemic caused by severe acute respiratory syndrome 2 virus (SARS-CoV-2) infection, has caused millions of infections and fatalities worldwide. Extensive SARS-CoV-2 research has been conducted to develop therapeutic drugs and prophylactic vaccines, and even though some drugs have been approved to treat SARS-CoV-2 infection, treatment efficacy remains limited. Therefore, preventive vaccination has been implemented on a global scale and represents the primary approach to combat the COVID-19 pandemic. Approved vaccines vary in composition, although vaccine design has been based on either the key viral structural (spike) protein or viral components carrying this protein. Therefore, mutations of the virus, particularly mutations in the S protein, severely compromise the effectiveness of current vaccines and the ability to control COVID-19 infection. This review begins by describing the SARS-CoV-2 viral composition, the mechanism of infection, the role of angiotensin-converting enzyme 2, the host defence responses against infection and the most common vaccine designs. Next, this review summarizes the common mutations of SARS-CoV-2 and how these mutations change viral properties, confer immune escape and influence vaccine efficacy. Finally, this review discusses global strategies that have been employed to mitigate the decreases in vaccine efficacy encountered against new variants.
Collapse
Affiliation(s)
- Ziyao Zhao
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia; (Z.Z.); (S.B.); (I.T.)
| | - Sahra Bashiri
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia; (Z.Z.); (S.B.); (I.T.)
| | - Zyta M. Ziora
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia;
| | - Istvan Toth
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia; (Z.Z.); (S.B.); (I.T.)
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia;
- School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia
| | - Mariusz Skwarczynski
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia; (Z.Z.); (S.B.); (I.T.)
| |
Collapse
|